Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8352W HIGH $7.64
Volume
1.47 K
Value Traded
46.96 K
Short % Float
0.59%
+4.3%Week
-6.62%1 Month
-26.51%3 Month
+45.22%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.53 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
15.05 M
Total Shares
5.78 M
Float Shares
2.54 M
Insiders
52.90%
Institutions
0.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NCEL Catalyst Timeline
Dated clinical, regulatory and corporate events for NewcelX Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NewcelX Ltd.
294Total events
6Upcoming
69Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Pre IND MeetingNCEL-101FDA Meeting
Successful FDA Pre-IND meeting for NCEL-101
type 1 diabetessource ↗
▲Patent GrantedNCEL-101IP / Competition
Brazilian patent granted for NCEL-101 manufacturing process
type 1 diabetessource ↗
▲Type B MeetingNCEL-101FDA Meeting
FDA Type B Pre-IND meeting completed for NCEL-101 in combination with tegoprubart
type 1 diabetessource ↗
▲Type B MeetingNCEL-101FDA Meeting
Successful FDA Type B Pre-IND meeting for NCEL-101
type 1 diabetessource ↗
▲Pre IND MeetingNCEL-101FDA Meeting
Successful FDA Pre-IND meeting for NCEL-101
type 1 diabetessource ↗
◆Trial CompletionMazindolTrial
Preclinical study expected to be completed within 12-18 months
fentanyl dependencesource ↗
●Type B MeetingNCEL-101FDA Meeting
Type B Pre-IND meeting with FDA on NCEL-101 development strategy
Type 1 Diabetessource ↗
▲FDA Feedback ReceivedNCEL-101FDA Meeting
FDA feedback received following Type B Pre-IND meeting
Type 1 Diabetessource ↗
▲PublicationAstroRxPresentation
Successful completion of Phase 1/2a clinical trial in ALS (mentioned in publication context)
amyotrophic lateral sclerosissource ↗
◆Pre IND MeetingNCEL-101FDA Meeting
Type B pre-IND meeting scheduled with FDA for NCEL-101
type 1 diabetessource ↗
●IND SubmissionNCEL-101IND
Pre-IND briefing package submitted to FDA for NCEL-101
type 1 diabetessource ↗
▲Partnership / LicenseNCEL-101Corporate
Strategic collaboration with Eledon Pharmaceuticals for tegoprubart
Type 1 Diabetessource ↗
◆Oral PresentationNCEL-101Presentation
Presentation at Swiss Biotech Conference
Type 1 Diabetessource ↗
▼Equity OfferingCorporate
Pricing of $1.35 million equity financing at $2.75 per share (30% premium)
▲Partnership / LicenseNCEL-101Corporate
Strategic collaboration with Eledon Pharmaceuticals to combine NCEL-101 with tegoprubart
Type 1 Diabetessource ↗
▲PublicationMazindolPresentation
Peer-reviewed publication of Mazindol IR/SR review in Clinical Drug Investigation
CNS disorders (narcolepsy, ADHD, substance use disorders)source ↗
▲PublicationPresentation
Publication of collaborative study on advanced biomaterial approaches for stem cell-derived islet delivery in Diabetology
Type 1 Diabetessource ↗
▲Patent GrantedIP / Competition
Publication of DOXA patent application in China
neurological diseasessource ↗
◆AcquisitionCorporate
Combined company NewCelX Ltd. to list on Nasdaq under NCEL starting October 31, 2025
●Other Regulator MilestoneEx-US Regulatory
Delisting of Kadimastem ordinary shares from TASE expected
▲AcquisitionCorporate
Merger of NLS Pharmaceutics and Kadimastem completed, combined company renamed NewcelX
●IND Enabling CompleteAEX-635Preclinical
Preparing for IND-enabling studies for AEX-635
Parkinson's disease, gliopathiessource ↗
▲Patent GrantedAEX-6xxIP / Competition
International patent applications WO2024141660 and WO2024115797 advancing through national phases
▲Partnership / LicenseCorporate
BIRD Foundation continues support for ITOL-102 program under merged company NewCelX
▲Partnership / LicenseCorporate
Kadimastem and TargetGene sign MOU for strategic collaboration on gene-edited cell therapies
▲Manufacturing MilestoneCMC / Inspection
Technology transfer, training, and product release certification completed with Pluri Inc.
●Preclinical PoCPreclinical
In-vivo preclinical safety studies to be conducted in preparation for Phase 1 trial
▲Partnership / LicenseCorporate
Preclinical partnering and co-development discussions planned for Q4 2025
▲FDA Filing AcceptedRegulatory Filing
SEC declares effective registration statement on Form F-4 for proposed merger
▲Patent GrantedIsletRxIP / Competition
Hong Kong patent granted for cell-selection and enrichment technology for IsletRx
insulin-dependent diabetessource ↗
▲Milestone PaymentiTOL-102Corporate
BIRD Foundation approves additional milestone payment for iTOL-102 co-development
Type 1 diabetessource ↗
▲Equity OfferingCorporate
Raised more than $6 million in aggregate to support merger and clinical trials
●Poster PresentationAEX-2Presentation
Poster presentation on AEX-2 and AEX-41 at ASCP Annual Meeting
narcolepsy and related neurological disorderssource ↗
●Poster PresentationAEX-41Presentation
Poster presentation on AEX-2 and AEX-41 at ASCP Annual Meeting
narcolepsy and related neurological disorderssource ↗
▲Preclinical PoCmazindolPreclinical
Positive results from Study KO-943 demonstrating Mazindol reduces fentanyl-induced reward in mice
fentanyl use disordersource ↗
▼Equity OfferingCorporate
Raised up to $3 million and signed $25 million committed equity facility agreement
Past FDA Catalysts and PDUFA Decisions
How NCEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$4M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 58%
Micro Cap(rank 382 of 658)
Percentile Rank
NewcelX Ltd. faces pipeline headwinds (34/100), with $660M risk-adjusted pipeline value, led by Mazindol in Attention Deficit Disorder With Hyperactivity (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mazindol Small moleculeCompletedNCT02808104 | Attention Deficit Disorder With Hyperactivity | Phase 2 | COMPLETED | 84 | Mar 28, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every NCEL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AstroRx® | multiple sclerosis | Phase 1/2a | 2026-06-15 | enhance myelin debris clearance by microglia; support lymphocyte-mediated immune regulation; accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytesRead More | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Samuel OlivierDirector | Buy | 81,818 81,818 held | $2.75 | 04/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NCEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NCEL for Q2 2026. | ||||
NCEL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NCEL ranks across every disease it competes in
Competitive Position is a premium feature
See how NCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNCEL News
NCELNewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
NewcelX Ltd. will attend the Breakthrough T1D Clinical & Research Congress from October 9-11, 2026, in Philadelphia. The management team aims to discuss their lead program, NCEL-101, which is set for a Phase 1/2a clinical trial. This follows a successful Pre-IND meeting with the FDA, providing clarity on the regulatory pathway for NCEL-101.
Read more →NCELNewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
NewcelX Ltd. has announced a $1.4 million equity financing at a 20% premium to its last closing price. The private placement involves selling 347,134 common shares and warrants, with proceeds aimed at advancing its lead program, NCEL-101, for type 1 diabetes. The offering is expected to close around August 14, 2026, pending customary conditions.
Read more →NCELNewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
NewcelX Ltd. has been granted a patent in Brazil for its NCEL-101 therapy aimed at treating type 1 diabetes. This patent protects the manufacturing process until November 2036 and follows a successful FDA Type B Pre-IND meeting. The company aims to address the unmet medical needs of the growing type 1 diabetes population in Brazil, which is approximately 500,000 individuals. The patent strengthens NewcelX's global intellectual property portfolio and enhances future partnership opportunities.
Read more →NCEL▲ +5.5%on this news
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
NewcelX has appointed Dr. Camillo Ricordi to its Scientific Advisory Board, enhancing its focus on developing regenerative therapies for type 1 diabetes. This appointment follows a successful FDA Type B Pre-IND meeting for their lead program, NCEL-101, which outlines a clear regulatory path for upcoming clinical trials. Dr. Ricordi's extensive experience in diabetes research is expected to significantly support NewcelX's strategic initiatives.
Read more →NCELNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
NewcelX Ltd. announced a successful Type B Pre-IND meeting with the FDA, receiving positive feedback on its development strategy for NCEL-101, a treatment for type 1 diabetes. The FDA's guidance allows NewcelX to advance toward clinical trials in combination with Eledon Pharmaceuticals' tegoprubart. This milestone is seen as a significant step toward developing a potentially transformative therapy for patients.
Read more →NCELNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
NewcelX has published a peer-reviewed study in Stem Cell Reports highlighting the potential of its AstroRx® therapy for treating chronic demyelinating diseases, including multiple sclerosis. The study demonstrates AstroRx®'s ability to enhance myelin debris clearance and promote oligodendrocyte differentiation. This publication supports NewcelX's ongoing development of scalable stem cell therapies and its lead candidate for type 1 diabetes.
Read more →NCEL▼ -7%on this news
To the shareholders of NewcelX AG, Kloten, Switzerland Zurich, June 5, 2026 Invitation to the Ordinary Shareholders' Meeting of NewcelX AG, Kloten, Switzerland Dear Shareholder, The board of directors of NewcelX A
NewcelX AG has invited shareholders to its ordinary shareholders' meeting scheduled for June 30, 2026. Key agenda items include the re-election of board members, approval of statutory financial statements for 2025, and examination of the compensation report. The company reported an operating loss for the year 2025, with an accumulated loss amounting to CHF 90,869,091. The board proposes to carry forward this loss to the next financial year, emphasizing the importance of stable governance amidst financial challenges.
Read more →NCEL▲ +9.5%on this news
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
NewCelX Ltd. has submitted a Pre-IND package to the FDA for NCEL-101, aiming to advance to a First-In-Human clinical trial for type 1 diabetes treatment. The therapy combines NCEL-101 with Eledon's tegoprubart, which has shown promise in preserving islet function in prior studies. A Type B pre-IND meeting is scheduled with the FDA to discuss further development plans.
Read more →NCEL▲ +28.9%on this news
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX reported its financial results for 2025 and highlighted its collaboration with Eledon Pharmaceuticals on NCEL-101, a potential treatment for Type 1 Diabetes. The company closed a financing round of approximately $3.4 million and appointed a new Chief Medical Officer to enhance its scientific leadership. Looking ahead, NewcelX anticipates accelerated development in 2026, despite facing financial losses and regulatory uncertainties.
Read more →NCEL▲ +6.4%on this news· ran to +85% by day 3
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Ltd. has updated its corporate presentation to emphasize its collaboration with Eledon Pharmaceuticals and the advancement of its Type 1 Diabetes program, NCEL-101. This partnership aims to integrate stem-cell-derived therapies with immune-modulation strategies to improve transplant outcomes. The company plans to showcase this strategy at the upcoming Swiss Biotech Conference.
Read more →NCEL▲ +10.8%on this news
NewcelX Announces Pricing of $1.35 Million Equity
NewcelX Ltd. has announced the pricing of a $1.35 million equity financing at a 30% premium over the last closing price. This funding will support the advancement of its lead program, NCEL-101, aimed at treating Type 1 Diabetes. The financing reflects strong confidence from investors and includes participation from existing shareholders. The expected closing date for the offering is around April 15, 2026, conditional on customary closing conditions being met.
Read more →NCELNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals
NewcelX has entered a strategic collaboration with Eledon Pharmaceuticals to enhance its NCEL-101 program for Type 1 Diabetes. This partnership aims to integrate NewcelX's stem-cell-derived therapies with Eledon's investigational anti-CD40L monoclonal antibody, facilitating improved immune modulation. The collaboration is expected to support better durability of cell grafts and streamline regulatory processes. Both companies anticipate that this initiative will help address critical unmet medical needs in diabetes treatment and advance clinical programs more efficiently.
Read more →NCELNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX has announced a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program aimed at treating Type 1 Diabetes. This partnership will integrate stem-cell-derived islets with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, to enhance graft survival. The collaboration is expected to streamline development and establish a clearer regulatory pathway for NCEL-101.
Read more →NCELNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Ltd. announced a peer-reviewed publication that validates the clinical profile of Mazindol Immediate-Release/Sustained-Release (IR/SR), strengthening its strategic positioning in licensing and acquisition discussions. The article, published in a reputable journal, enhances buyer confidence and supports NewcelX's ongoing negotiations to maximize the asset's value under the Contingent Value Rights (CVR) framework. The company is currently engaged in advanced talks with multiple parties interested in licensing or acquiring Mazindol ER, aiming to convert its scientific strengths into successful financial outcomes. This significant milestone reflects over 20 years of research and development dedicated to the drug's potential applications in various CNS disorders.
Read more →NCELNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Ltd. has updated its corporate presentation ahead of key spring 2026 investor conferences, emphasizing its focus on Type 1 Diabetes cell therapy. The presentation highlights recent scientific advancements and the addition of experienced leaders to its team. The company aims to engage with investors and partners to advance its clinical programs.
Read more →NCEL▲ +13.7%on this news
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes
NewcelX has announced positive results from an international study investigating advanced biomaterial approaches for stem cell-derived islet delivery in type 1 diabetes. The research, conducted in collaboration with several universities and organizations, demonstrated that engineered scaffolds incorporating extracellular matrix from a decellularized human pancreas could support islet function effectively. The study's findings align with NewcelX's focus on developing scalable stem cell therapies aimed at treating type 1 diabetes without the need for chronic immune suppression. This progress is supported by additional funding from organizations such as the Australian Foundation for Diabetes Research and Breakthrough T1D.
Read more →NCEL▲ +13.7%on this news
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Ltd. reported positive results from an international study on advanced biomaterial strategies for stem cell-derived islet delivery in Type 1 Diabetes. The research demonstrated that engineered scaffolds with extracellular matrix support islet function effectively. This aligns with NewcelX's goal of developing cell therapies that eliminate the need for immunosuppression.
Read more →About NewcelX Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next NCEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime